Literature DB >> 8405310

A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam.

E J Van Ameijden1, J A Van den Hoek, G H Mientjes, R A Coutinho.   

Abstract

In the present study data on the incidence of HBV and HCV were used to indicate the prevalence of and trends in risk behavior, assuming that drug users (DUs) who become infected with HBV or HCV are also at risk for infection with HIV. In addition, we determined to that extent the transmission patterns of HIV, HBV and HCV differed. DUs were selected from a cohort study in Amsterdam, had at least one follow-up visit between December 1985 and September 1989 and reported never to have had homosexual contacts. Among 305 DUs, of whom 70% injected recently, the prevalence of HIV, HBV and HCV were 31%, 68% and 65% respectively. These prevalences were strongly interrelated and the same risk factors were found. The cumulative incidence of either HIV or HBV or HCV was 30% among prevalent HIV-negatives. Despite a previously reported reduction in risk behavior, only the HIV incidence tended to decrease initially, and after 1986 the incidences of HIV, HBV and HCV remained disturbingly high and stable (mean: 4, 9 and 10 per 100 person-years, respectively). As at present HBV appears to be transmitted more heterosexually than HIV in our study group and the HIV-epidemic may follow the HBV-epidemic in its transmission patterns, preventive activities targeted at both injecting and sexual behavior should be expanded.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405310     DOI: 10.1007/bf00146260

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  32 in total

1.  Second generation (RIBA) test in diagnosis of chronic hepatitis C.

Authors:  P Marcellin; M Martinot-Peignoux; N Boyer; M Pouteau; P Aumont; S Erlinger; J P Benhamou
Journal:  Lancet       Date:  1991-03-02       Impact factor: 79.321

2.  The incidence of HBV infection and syringe exchange programs.

Authors:  H Hagan; T Reid; D C Des Jarlais; D Purchase; S R Friedman; T A Bell
Journal:  JAMA       Date:  1991-09-25       Impact factor: 56.272

3.  Incidence of acute hepatitis B in injecting drug users as an indicator of continuing HIV transmission--international implications.

Authors:  A Mele; G Rezza; M A Stazi; O N Gill; P Pasquini
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

4.  Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis.

Authors:  M J Alter; P J Coleman; W J Alexander; E Kramer; J K Miller; E Mandel; S C Hadler; H S Margolis
Journal:  JAMA       Date:  1989-09-01       Impact factor: 56.272

5.  Heterosexuals at risk for HIV: differences between private and commercial partners in sexual behaviour and condom use.

Authors:  C Hooykaas; J van der Pligt; G J van Doornum; M M van der Linden; R A Coutinho
Journal:  AIDS       Date:  1989-08       Impact factor: 4.177

6.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

7.  Prevalence of hepatitis C virus infections among heterosexuals with multiple partners.

Authors:  G J van Doornum; C Hooykaas; M T Cuypers; M M van der Linden; R A Coutinho
Journal:  J Med Virol       Date:  1991-09       Impact factor: 2.327

8.  Prevalence of HIV, hepatitis B and associated risk behaviours in clients of a needle-exchange in central London.

Authors:  G J Hart; N Woodward; A M Johnson; J Tighe; J V Parry; M W Adler
Journal:  AIDS       Date:  1991-05       Impact factor: 4.177

9.  The harm reduction approach and risk factors for human immunodeficiency virus (HIV) seroconversion in injecting drug users, Amsterdam.

Authors:  E J van Ameijden; J A van den Hoek; H J van Haastrecht; R A Coutinho
Journal:  Am J Epidemiol       Date:  1992-07-15       Impact factor: 4.897

10.  Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users.

Authors:  E Chamot; B Hirschel; J Wintsch; C F Robert; V Gabriel; J J Déglon; S Yerly; L Perrin
Journal:  AIDS       Date:  1990-12       Impact factor: 4.177

View more
  48 in total

1.  Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions.

Authors:  E J van Ameijden; R A Coutinho
Journal:  J Epidemiol Community Health       Date:  2001-05       Impact factor: 3.710

2.  Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?

Authors:  V D Hope; A Judd; M Hickman; T Lamagni; G Hunter; G V Stimson; S Jones; L Donovan; J V Parry; O N Gill
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

3.  Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif.

Authors:  J Lorvick; A H Kral; K Seal; L Gee; B R Edlin
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

4.  Factors associated with adolescent initiation of injection drug use.

Authors:  C M Fuller; D Vlahov; A M Arria; D C Ompad; R Garfein; S A Strathdee
Journal:  Public Health Rep       Date:  2001       Impact factor: 2.792

5.  Case-reporting of acute hepatitis B and C among injection drug users.

Authors:  Holly Hagan; Nadine Snyder; Eileen Hough; Tianji Yu; Shelly McKeirnan; Janice Boase; Jeffrey Duchin
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

6.  Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study.

Authors:  Paula J Lum; Kristen C Ochoa; Judith A Hahn; Kimberly Page Shafer; Jennifer L Evans; Andrew R Moss
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

Review 7.  Updating the infection risk reduction hierarchy: preventing transition into injection.

Authors:  David Vlahov; Crystal M Fuller; Danielle C Ompad; Sandro Galea; Don C Des Jarlais
Journal:  J Urban Health       Date:  2004-03       Impact factor: 3.671

8.  Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours.

Authors:  C Matheï; E Wollants; J Verbeeck; M Van Ranst; G Robaeys; P Van Damme; F Buntinx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

9.  Effects of race, neighborhood, and social network on age at initiation of injection drug use.

Authors:  Crystal M Fuller; Luisa N Borrell; Carl A Latkin; Sandro Galea; Danielle C Ompad; Steffanie A Strathdee; David Vlahov
Journal:  Am J Public Health       Date:  2005-04       Impact factor: 9.308

10.  Injecting risk behavior among drug users in Amsterdam, 1986 to 1992, and its relationship to AIDS prevention programs.

Authors:  E J van Ameijden; A R van den Hoek; R A Coutinho
Journal:  Am J Public Health       Date:  1994-02       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.